The user shared progress pictures showing hair thickening after 3 months of using a topical treatment of 0.3/6% finasteride/minoxidil. They also maintained their hair health with 1% Nizoral twice a week and dermastamping every 1.5-2 weeks.
The user reported progress in hair loss treatment using oral finasteride, keto 2% shampoo, and vitamin D. They experienced reduced hair fall, fewer scalp issues, and hope for improved hair density.
The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.
A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.
A user discusses making DIY dutasteride capsules from powder bought from China, using a mix of MCT oil and propylene glycol. Others warn about the risks of incorrect dosing, potential degradation, and the possibility of receiving fake products.
Minoxidil foam absorption concerns, with suggestions to use gloves or apply directly to the scalp to ensure proper absorption. Some users recommend using a scalp massager or switching to liquid minoxidil for better application.
The conversation discusses using minoxidil and finasteride for hair loss, with concerns about absorption and considering adding tretinoin for better results. Microneedling is suggested as a method to improve absorption, with varying depths and frequencies recommended.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.